ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO)
CUSIP: 00166B105
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock, par value $0.001 per share
- Shares outstanding
- 132,496,020
- Total 13F shares
- 29,030,607
- Share change
- -5,719,654
- Total reported value
- $12,060,366
- Put/Call ratio
- 22%
- Price per share
- $0.42
- Number of holders
- 58
- Value change
- -$2,784,536
- Number of buys
- 18
- Number of sells
- 63
Quarterly Holders Quick Answers
What is CUSIP 00166B105?
CUSIP 00166B105 identifies ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 00166B105:
Top shareholders of ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| LSV Associates, LLC |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
4,526,963
|
$61,575,751 | — | 13 Dec 2021 | |
| venBio Partners LLC |
13F
|
Company |
7.3%
|
9,699,925
|
$6,043,053 | — | 31 Mar 2025 | |
| HBM Healthcare Investments (Cayman) Ltd. |
13D/G
|
— |
8.4%
|
4,500,000
|
$2,295,000 | +$547,266 | 31 Mar 2025 | |
| Redmile Group, LLC |
13F
13D/G
|
Company |
8.5%
from 13D/G
|
3,640,834
|
$2,268,240 | — | 31 Mar 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
2.4%
|
3,158,265
|
$1,967,599 | — | 31 Mar 2025 | |
| TANG CAPITAL PARTNERS LP |
13D/G
|
TANG CAPITAL MANAGEMENT, LLC |
6.3%
|
3,296,883
|
$1,681,410 | $0 | 31 Dec 2024 | |
| BlackRock, Inc. |
13F
|
Company |
1.7%
|
2,313,800
|
$1,441,497 | — | 31 Mar 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
1.4%
|
1,837,923
|
$1,145,026 | — | 31 Mar 2025 | |
| FMR LLC |
13D/G
13F
|
Company |
3.4%
|
1,798,875
|
$917,426 | $0 | 29 Nov 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1.1%
|
1,451,778
|
$904,458 | — | 31 Mar 2025 | |
| Almitas Capital LLC |
13F
|
Company |
1%
|
1,353,141
|
$843,007 | — | 31 Mar 2025 | |
| Sophia Randolph |
3/4/5
|
CHIEF MEDICAL OFFICER |
—
mixed-class rows
|
420,711
mixed-class rows
|
$840,334 | — | 14 Aug 2024 | |
| ACADIAN ASSET MANAGEMENT LLC |
13F
|
Company |
0.98%
|
1,296,331
|
$806,000 | — | 31 Mar 2025 | |
| Jaume Pons |
3/4/5
|
PRESIDENT & CSO |
—
mixed-class rows
|
773,821
mixed-class rows
|
$666,412 | — | 19 Feb 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.71%
|
944,084
|
$588,164 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.58%
|
770,907
|
$480,372 | — | 31 Mar 2025 | |
| Deutsche Girozentrale DekaBank |
13F
|
Individual |
0.03%
|
41,000
|
$468,000 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
0.54%
|
718,853
|
$447,845 | — | 31 Mar 2025 | |
| BANK OF MONTREAL /CAN/ |
13F
|
Company |
0.52%
|
682,394
|
$425,131 | — | 31 Mar 2025 | |
| TWO SIGMA ADVISERS, LP |
13F
|
Company |
0.51%
|
681,000
|
$424,263 | — | 31 Mar 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
0.42%
|
550,000
|
$342,650 | — | 31 Mar 2025 | |
| TWO SIGMA INVESTMENTS, LP |
13F
|
Company |
0.41%
|
542,655
|
$338,074 | — | 31 Mar 2025 | |
| Privium Fund Management B.V. |
13F
|
Company |
0.38%
|
509,059
|
$317,144 | — | 31 Mar 2025 | |
| Peter S. Garcia |
3/4/5
|
CHIEF FINANCIAL OFFICER |
—
mixed-class rows
|
201,516
mixed-class rows
|
$313,511 | — | 14 Aug 2024 | |
| LOS ANGELES CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.31%
|
409,938
|
$255,391 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.28%
|
373,214
|
$232,512 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.27%
|
358,460
|
$223,321 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.27%
|
357,957
|
$223,007 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.24%
|
318,183
|
$198,228 | — | 31 Mar 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.2%
|
271,197
|
$168,142 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.19%
|
256,493
|
$159,795 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.16%
|
211,051
|
$131,485 | — | 31 Mar 2025 | |
| Nuveen, LLC |
13F
|
Company |
0.12%
|
164,790
|
$102,664 | — | 31 Mar 2025 | |
| COMMONWEALTH EQUITY SERVICES, LLC |
13F
|
Company |
0.12%
|
153,777
|
$96,000 | — | 31 Mar 2025 | |
| Qube Research & Technologies Ltd |
13F
|
Company |
0.11%
|
146,977
|
$91,567 | — | 31 Mar 2025 | |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP |
13F
|
Company |
0.09%
|
121,710
|
$75,825 | — | 31 Mar 2025 | |
| AQR CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.09%
|
119,050
|
$74,168 | — | 31 Mar 2025 | |
| BANK OF NOVA SCOTIA |
13F
|
Company |
0.08%
|
105,858
|
$65,950 | — | 31 Mar 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.08%
|
101,113
|
$62,690 | — | 31 Mar 2025 | |
| XTX Topco Ltd |
13F
|
Company |
0.07%
|
92,259
|
$57,477 | — | 31 Mar 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.07%
|
89,199
|
$55,571 | — | 31 Mar 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.06%
|
75,900
|
$47,286 | — | 31 Mar 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.06%
|
73,836
|
$46,000 | — | 31 Mar 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.05%
|
71,730
|
$44,688 | — | 31 Mar 2025 | |
| Aberdeen Group plc |
13F
|
Company |
0.05%
|
66,211
|
$41,249 | — | 31 Mar 2025 | |
| SEI INVESTMENTS CO |
13F
|
Company |
0.05%
|
60,795
|
$37,875 | — | 31 Mar 2025 | |
| BARCLAYS PLC |
13F
|
Company |
0.04%
|
48,029
|
$29,922 | — | 31 Mar 2025 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.03%
|
46,302
|
$28,839 | — | 31 Mar 2025 | |
| Nan Fung Group Holdings Ltd |
13F
|
Company |
0.03%
|
41,950
|
$26,135 | — | 31 Mar 2025 | |
| WEALTH ENHANCEMENT ADVISORY SERVICES, LLC |
13F
|
Company |
0.03%
|
40,551
|
$25,262 | — | 31 Mar 2025 |
Institutional Holders of ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) as of Q2 2025
As of 30 Jun 2025,
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO) was held by
58 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
29,030,607 shares.
The largest 10 holders included
venBio Partners LLC, Redmile Group, LLC, TANG CAPITAL MANAGEMENT LLC, Almitas Capital LLC, VANGUARD GROUP INC, ACADIAN ASSET MANAGEMENT LLC, BANK OF AMERICA CORP /DE/, BlackRock, Inc., TWO SIGMA ADVISERS, LP, and BANK OF MONTREAL /CAN/.
This page lists
58
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
83
Q2 2025 holders
58
Holder diff
-25
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.